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Background: Demographic changes have led to an increase in the number of elderly frail persons and, consequently,
systematic geriatric assessment is more important than ever. Frailty Indexes (FI) may be particularly useful to
discriminate between various degrees of frailty but are not routinely assessed due, at least in part, to the
large number of deficits assessed (from 30 to 70). Therefore, we have developed a new, more concise FI for
rapid geriatric assessment (RGA)—the Frail-VIG index (“VIG” is the Spanish/Catalan abbreviation for Comprehensive
Geriatric Assessment), which contains 22 simple questions that assess 25 different deficits. Here we describe this FI and
report its ability to predict mortality at 24 months.
Methods: Prospective, observational, longitudinal study of geriatric patients followed for 24 months or until death. The
study participants were patients (n = 590) admitted to the Acute Geriatric Unit at the at the University Hospital of Vic
(Barcelona) during the year 2014. Participants were classified into one of seven groups based on their Frail-VIG score
(0–0.15; 0.16–0.25; 0.26–0.35; 0.36–0.45; 0.46–0.55; 0.56–0.65; and 0.66–1). Survival curves for these groups were
compared using the log-rank test. ROC curves were used to assess the index’s capacity to predict mortality at
24 months.
Results: Mean (standard deviation) patient age was 86.4 (5.6) years. The 24-month mortality rate was 57.3%
for the whole sample. Significant between-group (deceased vs. living) differences (p < 0.05) were observed for
most index variables. Survival curves for the seven Frail-VIG groups differed significantly (X2 = 433.4, p < 0.001),
with an area under the ROC curve (confidence interval) of 0.90 (0.88–0.92) at 12 months and 0.85 (0.82–0.88)
at 24 months. Administration time for the Frail-VIG index ranged from 5 to 10 min.
Conclusions: The Frail-VIG index, which requires less time to administer than previously validated FIs, presents
a good discriminative capacity for the degree of frailty and a high predictive capacity for mortality in the present cohort.
Although more research is needed to confirm the validity of this instrument in other populations and settings, the
Frail-VIG may provide clinicians with a RGA method and also a reliable tool to assess frailty in routine practice.
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Frailty is considered a clinical state in which the individual
is more vulnerable to becoming dependent and/or in
which there is a higher risk of death if exposed to a stressor
[1]. Together with multimorbidity, frailty is one of the most* Correspondence: jordiamblas@gmail.com
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and both are closely associated with adverse health
outcomes [3–5]. Despite controversies surrounding the
optimum operational definition of frailty, there is a strong
consensus among clinicians that frailty should be evaluated
whenever feasible [6–8]. Two complementary approaches
to assessing frailty that may be useful in different circum-
stances and for different purposes are Fried’s frailty
syndrome approach [9, 10], which may be particularly
useful for population screening to identify pre-disability
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particularly useful to discriminate between various degrees
of frailty [13].
A wide variety of frailty indices (FIs) have been devel-
oped [3, 4, 12, 14, 15] -with the main differences among
them being the number of domains [16] and deficits
assessed (from 30 to 70 deficits) [12]. In most FIs, the
probability of dying increases exponentially as the rate of
deficit accumulation increases [14, 17–20]. Current FIs
assess frailty on a scale ranging from 0 to 1, with scores
from 0.2 [15] to 0.25 [21] indicating frailty. A score of
0.7 is usually considered the cut-off point to indicate
that homeostasis has reached its limit and thus any add-
itional deficits would likely result in death [16, 22]. The
multidimensional nature of FIs is a characteristic that
these instruments share with comprehensive geriatric as-
sessment (CGA). Indeed, the close relation between FIs
and CGA is not new: a study published in 2004 demon-
strated that it was both clinically justified and operation-
ally feasible to develop an FI based on geriatric
assessment (FI-CGA) [23].
Despite the growing number of elderly persons with
multimorbidity and frailty [24–26], which implies a
need for healthcare providers to make geriatric assess-
ment a routine part of healthcare delivery [27], the
use of a complete CGA and/or FIs remain underuti-
lized in many settings [28]. One of the main reasons for
this lack of widespread adoption, particularly in the context
of acute care hospitals [29–32], could be the amount of
time needed to administer these instruments [14]. In this
context, and given the importance of performing a situ-
ational diagnosis/assessment of the degree of frailty as the
starting point for individualized decision-making [33],
newer, more pragmatic and faster multidimensional tools
are needed [34].Aims
Based on the multidimensional approach of the CGA and
inspired by the simplicity and potential universal applicabil-
ity of the Rapid Geriatric Assessment (RGA) [34], together
with the known value of the FI methodology, we have
developed a new FI called the “Frail-VIG index” (VIG is the
Spanish/Catalan abbreviation for CGA). In the present
observational study, we prospectively applied the Frail-VIG
index to 590 patients admitted to the Acute Geriatric Unit
(AGU) at the University Hospital of Vic (Barcelona, Spain)
to determine the instrument’s capacity to predict mortality
at 24 months.Methods
Study design
This was a prospective, observational, longitudinal study.Context and participants
The study was conducted at the University Hospital of
Vic (Barcelona; Spain), a 200-bed acute care hospital
covering a population area of 156,000 inhabitants. All
patients admitted to the AGU during the year 2014 were
included. Admission criteria to the AGU were: 1) age ≥
85 years; or 2) cognitive decline; or 3) the presence of
advanced chronic conditions identified by the NECPAL
(NECesidades PALiativas, in Spanish; Palliative Care
Needs, in English) test [35], a validated tool for the early
diagnosis of the need for palliative care among individuals
with limited life expectancy. No exclusion criteria
were defined.Design and evaluation of the frail-VIG index
To design the most pragmatic instrument possible,
the Frail-VIG index was constructed using only
variables recorded during the usual clinical evaluation
process—as opposed to variables collected as part of an
epidemiological study, which is how most other FIs were
developed [12, 15, 18, 36, 37]. In our department, the
original aim was to systematically perform a CGA for all
patients; to achieve this, all health care professionals in the
department agreed by consensus to create a checklist that
included 40 multidimensional variables. Subsequently,
given the need for a quantifiable RGA for decision-making
at our acute care hospital [33], a proposal was made to
reduce the number of variables, prioritizing those variables
with the strongest prognostic capacity for mortality [38].
In the development of the Frail-VIG index, rather
than comparing the index to a “gold standard” instru-
ment, we sought to replicate the characteristics of a
previously validated instrument [3, 4, 12, 14, 15] and
then we evaluated its predictive ability [39]. Our
development process focused on two main areas: 1)
variable selection and construct development, and 2)
demonstration of the predictive validity for mortality.
The design of the Frail-VIG index has been previously
described [40].Variable selection and construct development
Published recommendations [15] suggest that all vari-
ables included in a FI must have the following char-
acteristics: 1) prevalence of the variable must increase
with age and be associated with health problems; 2) it
should not saturate too early; 3) it should not be ex-
cessively prevalent (> 80% of individuals ≥ age 85) or
rare (< 1%); and 4) the variable should cover a range
of systems and domains. To ensure the inclusion of
variables from a content validation process, we used a
multidimensional approach [4] in which we compared
the number of variables from each domain relative to
the total number of variables for the following five
Table 1 Description and characteristics of the Frail-VIG index
Domain Variable Description Points
Functional IADLs Money management Needs help managing financial matters (bank, shops, restaurants) Yes 1
No 0
Telephone use Needs help using the telephone Yes 1
No 0
Medication
management
Needs assistance in preparing or administering medications Yes 1
No 0
ADLs Barthel index (BI) No dependency (BI≥ 95) 0
Mild-moderate dependency (BI 90–65) 1
Moderate-severe dependency (BI 60–25) 2
Absolute dependency (BI ≤ 20) 3
Nutritional Malnutrition Weight loss ≥ 5% in the last 6 months Yes 1
No 0
Cognitive Degree of cognitive
impairment
No cognitive impairment 0
Mild-moderate cognitive impairment (equivalent to GDS≤ 5) 1
Severe-very severe cognitive impairment (equivalent to GDS≥ 6) 2
Emotional Depressive syndrome Need for antidepressant medication Yes 1
No 0
Insomnia/anxiety Frequent need for benzodiazepines or other psychiatric drugs with a sedative effect for
insomnia/anxiety
Yes 1
No 0
Social Social vulnerability Do health care professionals perceive the presence of social vulnerability? Yes 1
No 0
Geriatric
syndromes
Delirium Presence of delirium and/or behaviour disorder requiring antipsychotic drugs in the last
6 months.
Yes 1
No 0
Falls In the last 6 months, ≥2 falls or hospitalization due to a fall. Yes 1
No 0
Ulcers Presence of ulcer (pressure or vascular, any grade) Yes 1
No 0
Polypharmacy Taking≥ 5 drugs Yes 1
No 0
Dysphagia Difficulty swallowing when eating or drinking? Presence of aspiration respiratory infections
during the last 6 months?
Yes 1
No 0
Severe symptoms Pain Need for≥ 2 conventional analgesics and/or strong opioids for pain control Yes 1
No 0
Dyspnea Basal dyspnea impeding the ability to leave the house and/or opioids are frequently needed Yes 1
No 0
Diseases (+) Cancer Active cancer Yes 1
No 0
Respiratory Presence of any type of chronic respiratory disease (COPD, restrictive lung disease...) Yes 1
No 0
Cardiac Presence of any type of chronic heart disease (heart failure, ischemic cardiomyopathy,
arrhythmia)
Yes 1
No 0
Neurological Presence of any type of neurodegenerative disease (Parkinson, ALS,...) or a history of stroke
(ischemic or hemorrhagic).
Yes 1
No 0
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Table 1 Description and characteristics of the Frail-VIG index (Continued)
Domain Variable Description Points
Digestive Presence of any type of chronic digestive disease
(chronic liver disease, cirrhosis, chronic
pancreatitis, inflammatory bowel disease,…)
Yes 1
No 0
Renal Presence of chronic renal failure (GFR < 60) Yes 1
No 0
Frail-VIG index =
ADLs Basic Activities of Daily Living, IAVDs Instrumental Activities of Daily Living, ALS amyotrophic lateral sclerosis. COPD Chronic Obstructive Pulmonary Disease.
GFR Glomerular Filtration Rate, GDS Global Deterioration Scale. (+) two point are scored if the patient presents criteria for advanced chronic illness on the NECPAL
test (Annex 2; available at: http://ico.gencat.cat/web/.content/minisite/ico/professionals/documents/qualy/arxius/NECPAL-3.0-ENGLISH_full-version.pdf)
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tools: the CSHA-FI70 (Original Canadian Study of
Health and Aging–Frailty Index) [12], the CSHA-FI40
(Searle version of Canadian Study of Health and
Aging–Frailty Index) [15], the FI-CGA [23], the
SHARE-FI (Survey of Health, Ageing and Retirement in
Europe-Frailty Index) [41], and the MPI (Multidimensional
Prognostic Index) [42] (Additional file 1). It is also
advisable that the proportion of missing data be < 5% [43].
Theoretically, all FIs should include a minimum
number of functional deficits (ranging from 30 to 40)
to maintain their predictive capacity [15]; however, by
selecting variables according to severity and progres-
sion criteria [33] and grouping some of these together
(especially on the functional and cognitive domains),
we were able to limit the Frail-VIG index to only 22
questions assessing 25 deficits. Like other FIs, the
Frail-VIG index is obtained by dividing the accumu-
lated deficits by the total number of potential deficits,
for a score ranging from 0.0 (no deficits) to 1.0 (all
possible deficits).
Other requirements for the Frail-VIG index was
that it meet or exceed the characteristics of existing
FIs [4, 16] in terms of the submaximal limit for the
FI score (99% of individuals with an FI < 0.7) [16, 22]
and the asymmetric distribution density of FI scores
[44], and that the score be closely correlated with
mortality [14, 17].
Predictive validity
In order to demonstrate the predictive validity of the
index, the study design included a two-year follow-up
period. We determined final outcomes (living, deceased, or
lost to follow up) at month 24 using only data information
systems via the Shared Medical Record in Catalonia (HC3)
[45], an electronic database accessible to all healthcare
providers in Catalonia that allows for healthcare
professionals to reliably determine whether the patient is
“active” (alive) or deceased (including date of death).Variables and data sources
The variables included in Frail-VIG index are shown in
Table 1. These variables evaluate the following domains:
money, telephone and medication management—all of
which are common instrumental activities of daily living
(ADL); weight loss ≥5% in the last 6 months is considered
a marker of nutritional worsening; emotional markers
include the presence of depressive syndrome or insomnia/
anxiety; the subjective perception of social vulnerability by
the health care team is considered an indicator for the
social domain. The following geriatric syndromes are
assessed: delirium, falls, polypharmacy, and dysphagia.
Symptoms with severity criteria include pain and dyspnea.
Finally, the presence of chronic diseases (cancer, respiratory,
cardiac, neurological, digestive, and renal disease) are
also recorded.
In the calculation of the Frail-VIG, binary variables
are scored as “0 points” (no deficit) or “1 point”
(presence of the deficit), with the exception of
advanced chronic illness (defined according to the
NECPAL criteria; see Additional file 2), which was
scored as 2 points. For ordinal variables, the Frail-
VIG uses the well-accepted cut-off points used in
routine clinical practice for the Barthel Index (BI),
which is used to assess basic ADLs, categorized
according to the Saha criteria [46] and Reisberg’s
Global Deterioration Scale (GDS), which assesses
cognitive impairment, categorizing patients into one
of 3 groups [47].
To prevent intercurrent illnesses (that is, the condi-
tions that led to hospitalization) from influencing the
Frail-VIG score, the index score identifies only the
patient’s baseline condition (that is, ≥ 1 month before
hospitalization and/or prior to onset of the clinical
process leading to hospital admission). This information
is collected on the patient’s first day in the hospital by
interview (patient and/or family) to obtain a full medical
history and/or by checking the medical record to
determine current prescriptions.
Table 2 Descriptive results for the whole sample and comparative outcomes between surviving vs. non-surviving patients
Variable Total (n = 590) Death during the 24-month follow up p-value
Yes (n = 338) No (n = 252)
Mean age (years) 86.39 (+/−5.58) 86.55 (+/−5.76) 86.17 (+/−5.34) 0.420
Sex Men 251 (42.5%) 160 (63.7%) 91 (36.3%) 0.006
Women 339 (57.5%) 178 (52.5%) 161 (47.5%)
Advanced chronic disease Yes 260 (44.1%) 220 (84.6%) 40(15.4%)) < 0.001
No 330 (55.9%) 118 (35.8%) 212 (64.25%)
Length of hospital stay Mean days 5.88 (+/−3.26) 5.88(+/−3.36) 5.33(+/−3.12) 0.982
Destination after discharge Home 135 (22.9%) 59 (43.7%) 76 (56.3%) < 0.001
Residence 81 (13.7%) 45 (55.6%) 36 (44.4%)
Intermediate care facility 321 (54.4%) 181 (56.4%) 140 (43.6%)
Death 53 (9%)
IADLs (0–1–2-3) 0.85 (+/−1.15) 0.53 1.27 < 0.001
ADLs Mean Barthel index 62.81 (+/−29.71) 57.26 70.24 < 0.001
Malnurition 190 (32.2%) 175 (92.1%) 15 (7.9%) < 0.001
Cognitive Impairment None 231 (39.2%) 112 (48.5%) 119 (51.5%) < 0.001
Mild/Moderate 257 (43.6%) 154 (59.9%) 103 (40.1%)
Severe 102 (17.3%) 72 (70.6%) 30 (29.4%)
Emotional Status Euthymic mood 306 (51.9%) 175 (57.2%) 131 (42.8%) 0.166
Depressive syndrome 251 (42.5%) 139 (55.4%) 112 (44.6%)
Not evaluable 33 (5.6%) 24 (72.7%) 9 (27.3%)
Insomnia 337 (63.9%) 214 (63.5%) 123 (36.5%) < 0.001
Social Vulnerability 19 (3.2%) 14 (73.7%) 5 (26.3%) 0.142
Geriatric Syndromes Delirium 334 (56.6%) 220 (65.9%) 114 (34.1%) < 0.001
Falls 348 (59%) 197 (56.6%) 151 (43.4%) 0.689
Ulcers 76 (12.9%) 64 (84.2%) 12 (15.8%) < 0.001
Polypharmacy 474 (80.3%) 288 (60.8%) 186 (39.2%) 0.001
Dysphagia 255 (43.2%) 205 (80.4%) 50 (19.6%) < 0.001
Severe Symptoms Pain 146 (24.7%) 103 (70.5%) 43 (29.5%) < 0.001
Dyspnea 69 (11.7%) 59 (85.5%) 10 (14.5%) < 0.001
Chronic Diseases Cancer 87 (14.7%) 73 (83.9%) 14 (16.1%) < 0.001
Respiratory 164 (27.8%) 107 (65.2%) 57 (34.8%) 0.015
Cardiac 352 (59.7%) 233 (66.2%) 119 (33.8%) < 0.001
Neurological 155 (26.8%) 93 (60.0%) 62 (40.0%) 0.427
Digestive 68 (11.5%) 53 (77.9%) 15 (22.1%) < 0.001
Renal 291 (49.3%) 208 (71.5%) 83 (28.5%) < 0.001
ADLs Basic Activities of Daily Living, IADLs Instrumental Activities of Daily Living
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Descriptive statistics of the variables were calculated using
the SPSS software program (IBM; Chicago, IL; USA).
Statistical significance (p < 0.05) with 95% confidence
intervals was obtained by comparing mean values (for
quantitative variables) and percentages (for qualitative
variables).
Survival estimates were obtained for the 24-month
follow-up. The survival analysis was performed using theSurvival, pROC, and RMS packages from the R project
(https://www.r-project.org). Survival curves were computed
according to the Frail-VIG index scores, grouping these
according to predefined criteria before the analysis into
seven interval ranges (0–0.15, 0.16–0.25, 0.26–0.35,
0.36–0.45, 0.46–0.55, 0.56–0.65, and 0.66–1), and then
the survival curves were compared via the log-rank test.
The ROC curves were analysed to determine the predictive
capacity of the Frail-VIG index.
Fig. 1 Distribution of Frail-VIG index scores at baseline (n = 590)
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Cohort description and analysis of the variables
A total of 590 patients were included. Mean (standard
deviation; SD) patient age was 86.4 (5.6) years. Women
comprised 57.5% (n = 339) of the sample. Most (83.9%)
of the patients admitted to the AGU were frail (Frail-VIG
index score > 0.25). Fifty-three patients (8.9%) died during
hospitalization. No missing values were observed for any
of the study variables. Table 2 shows the descriptive
results for the study variables.
Variable selection and results of construct evaluation
The deficits included in the Frail-VIG index are those com-
monly associated with age and adverse health outcomes
and these deficits were carefully selected to represent the
main domains to be assessed (see Additional file 1).
The prevalence rate for each variable was < 80% (except
for polypharmacy, which was exactly 80%) and none could
be considered rare (< 1%). Although the prevalence for
some variables—for example, polypharmacy—was high,
none of these variables are universal, even in 85-year old
patients [48]. The overall construct validation process [4]
shows that the distribution of variables by domain (as a
percentage of the overall index) was similar to other
validated FIs (see Additional file 1). Despite the high mean
age of this population cohort and the large percentage of
individuals presenting with advanced chronic conditions,
the submaximal limit (0.7) for FI scores was maintained
(that is, the Frail-VIG index was < 0.7 in 99.3% of
patients). The distribution of scores on the Frail-VIG
index tended towards asymmetry (asymmetry coefficient,
0.37) (Fig. 1).
Mortality at 24 months
The cohort was followed for 24 months or until death,
whichever came first. At 24 months, the mortality rate
was 57.3% (n = 338). None of the patients were lost to
follow up. Table 2 shows differences in mortality rates
for each individual study variable. The mortality rate
increased progressively in line with higher Frail-VIG
scores (Fig. 2), especially at the 12 month follow up
(Fig. 2; panel A).
We evaluated the correlation between mortality and
the Frail-VIG index by means of the log-rank test (Fig. 3),
comparing the seven different survival curves based on
the score intervals described in the statistical analysis
section above. Highly significant differences were ob-
served between the various range intervals (X2 = 433.4,
p < 0.0001). Table 3 shows the number of individuals in
each frailty index category who had died at 24 months
of follow-up.
On the ROC curve analysis, the area under the curve
(AUC) values at 3, 6, 9, 12 and 24 months were, respect-
ively, as follows: 0.87 (range, 0.84–0.90), 0.88 (0.85–0.91),0.89 (0.87–0.92), 0.9 (0.88–0.92), and 0.85 (0.82–0.88)
(Additional file 3). The optimal cut-off point was 0.46 in
all cases, revealing a better performance (as measured by
the Youden index) at 12 months (0.62), with a sensitivity
and specificity of 0.80 and 0.83, respectively
(Additional file 4).
According to the participating clinicians, administration
time for the Frail-VIG index ranged from 5 to 10 min.Discussion
Key results
At the 24 month follow-up, we found statistically significant
differences (p < 0.05) between the two groups (living vs.
deceased) for most of the Frail-VIG variables, a finding that
confirms the index’s discriminative capacity. The only
variables that were not statistically significant were 1) social
vulnerability—likely due to the limited number of patients
with social vulnerability (19 patients; 3.2%), 2) emotional
status (although there were significant differences [p 0.016]
at the 12-month follow up), and 3) falls (probably because
we did not differentiate between severe and
non-severe falls).
These results, which met the previously-specified
internal validation criteria, support the validity of the
Frail-VIG index [16, 44]. All criteria were fully met, both
in terms of the variables included and with regard to the
construct’s validation criteria.
The strong correlation between the Frail-VIG index
score and mortality was consistent with published data
[14, 17]. The 12- and 24-month AUC were 0.90 and
0.85, respectively, demonstrating that the Frail-VIG
index offers a better prognostic capacity than other
previously published FIs (whose AUCs range from 0.6 to
0.8) [4, 14, 49, 50]. A study conducted by Pilotto et al.
evaluated several different FIs [51] in a group of hospi-
talized patients (20 Italian geriatric units; n = 2033),
reporting a 12-month AUC of 0.69 for the FI-SOF
Fig. 2 Distribution in number (n) and percentage (%) of surviving and non-surviving patients at 12 (panel a) and 24 (panel b) months according
to the Frail-VIG index score
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for the CSHA-FI70, 0.73 for the FI-CGA, and 0.75 for
the MPI. A study by Ritt et al. involving 307 hospitalized
inpatients in an AGU in Erlangen (Germany) compared
the predictive capacity of 3 different FIs based on CGA,
finding an AUC at 6 months that ranged from 0.77
to 0.84 [53].
Although the excellent predictive capacity of the
Frail-VIG index may seem surprising, we believe that
the following factors may have positively influenced our
results: (1) The characteristics of the instrument itself,
which incorporates only those variables that are
routinely used in conventional CGAs. Moreover, most ofthese variables are good predictors of mortality, as
evidenced by the statistically significant differences
between the two groups (alive vs. deceased) for practic-
ally all of the individual variables included in the index
(Table 2). (2) There were no missing data from the base-
line data due to the systematic data collection processes
during routine clinical practice of the health care team.
Similarly, no data were missing during follow up thanks
to the reliability of the “Shared Medical Record” system
in Catalonia (HC3). (3) The instrument was adminis-
tered by a small group of professionals with extensive
expertise in geriatric assessment. Although the question-
naire is both short and simple (containing only basic
Fig. 3 Kaplan–Meier curves according to Frail-VIG index score
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not know if administration of this instrument by
untrained staff or in other settings could lead to different
results; nor do we have any data on possible interob-
server variability. (4) We cannot rule out the possibility
of selection bias caused by the AGU admission criteria,
which could have led us to select a population with high
mortality rates. (5) The intercurrent process that led to
hospital admission may have affected the final mortality
results, potentially increasing specifically the mortality
rate in those patients who were the most frail prior to
admission.
When we compared the results at the 12 and 24 month
follow up periods, we found that the prognostic accuracy
of the index tends to decrease over time (Fig. 3, Table 3
and Additional files 3 and 4). The most plausible explan-
ation for this finding is the dynamic nature of frailty
[54]: the Frail-VIG index score for each patient reflects a
static vision of reality; that is, it indicates the patient’s
status only at the time of data collection. However, given
the patient profile of this cohort (elderly patients with
high multimorbidity rates), it is logical to expect that
these patients will continue to accumulate deficits
during the follow up period, thus increasing their
Frail-VIG index score; this would also explain 24 monthTable 3 People alive and deceased at 12 and 24 months follow-up
Frail-VIG index category 0.1 (0–0.15) 0.2 (0.16–0.25) 0.3 (0.26–
12 months Follow-up Alive 22 72 54
Deceased 0 1 7
Deceased (%) 0 1.4 11.4
24 months Follow-up Alive 19 61 45
Deceased 3 12 16
Deceased (%) 13.6 16.4 26.2
Total 22 73 61mortality in individuals whose initial Frail-VIG score
(< 0.25) did not indicate the presence of frailty.
Administration of the Frail-VIG index does not preclude
the use of the CGA for systematic multidimensional
assessment [55], but instead offers the advantage of a
RGA: only 5–10 min of time are needed to complete the
Frail-VIG; by contrast, the CSHA-FI70 [12] requires
around 20–30 min [21] and the FI-CGA [23] about
25 min [56].
Utility of the frail-VIG index
Although more studies will be needed to confirm the
benefits of using FIs to assess geriatric patients, we
believe the Frail-VIG index to be a valuable tool:
(1)The index can accurately discriminate between frail
and non-frail patients. The fact that more than 80% of
the patients admitted to the AGU—a unit specifically
designed for frail patients—are, in fact, frail, supports
the appropriateness of the unit’s admission criteria.
(2)The Frail-VIG index score assesses the degree of frailty
as a continuous variable. This can help clinicians make
an accurate situational diagnosis [31]: the ability to de-
termine the patient’s approximate biological age
(degree of frailty) relative to his/her chronological age,in each frailty index category
0.35) 0.4 (0.36–0.45) 0.5 (0.46–0.55) 0.6 (0.56–0.65) 0.7 (0.66–1) Total
113 50 5 0 316
48 73 115 30 274
45.3 70.7 97.5 100 46.4
88 36 3 0 252
73 87 117 30 338
45.3 70.7 97.5 100 57.3
161 123 120 30 590
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the treatment to develop an appropriate therapeutic
plan. For instance, identifying advanced, progressive
frailty (after potentially reversible causes have been
ruled out), helps in analysing the risk/benefit of
aggressive interventions. Conversely, assessing the
degree of frailty can also be useful in decision-making
for patients at risk of undertreatment who, though
having fair reserve, could be denied additional
diagnostic efforts or specific therapeutic interventions
due to age. Frailty assessment using FIs allow us to
reduce uncertainty by providing better understanding
on the patient’s overall situation, helping to improve
the dialogue between the patient, family and health
care professionals in regards to expectations and
objectives in the shared decision-making process
(Fig. 4).
(3)Related to the previous point, quantification of
the degree of frailty by means of the Frail-VIG
index could facilitate the creation of a common
reference for communication with health care
professionals in other specialities. In addition, this
could potentially allow clinicians to monitor the
results of any interventions. Finally, quantification
could be highly valuable in patient care and for
research purposes [18].
Study limitations and next steps
The data described here should be interpreted with caution
given that our cohort is not representative of the generalFig. 4 Conceptual Model of Situational Diagnosis (based on degree of frailpopulation. An important limitation of the present study is
that the Frail-VIG index has not been validated by compar-
ing it to other instruments in the same cohort, nor com-
pared to other variables (for example, institutionalization or
use of resources). Additional studies are required to assess
the reliability and reproducibility of this index in other set-
tings and populations. Some study variables were obtained
by reviewing the patient’s medications without confirming
the suitability of the prescription and/or dose for the pa-
tient’s condition; this approach to obtaining certain vari-
ables may have biased the study outcomes. Assessment of
certain variables (for example, social needs) needs to be im-
proved to increase the reliability and accuracy of the tool.
Finally, although the professionals agreed about the time
needed to administer the instrument (that is, more than
5 min but less than 10 min), we did not systematically
measure (using a timer) these data.
Finally, the next steps in the development of the
Frail-VIG index are the following: (1) validate the instru-
ment in an independent cohort, in other settings and
distinct populations; (2) demonstrate its applicability and
utility for professionals in routine clinical practice; and (3)
as with most FIs, the true challenge is to demonstrate
whether the routine, systematic use of this tool actually
improves the health outcomes of the patients in the “triple
aim” framework [57].
Conclusions
The Frail-VIG index was developed to facilitate frailty
assessment during routine clinical practice in order toty) and the proposed care objectives
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benefits of the Frail-VIG index are its simplicity—22
simple, dichotomous questions to assess 25 different
deficits—and short administration time (5 to 10 min),
which allows physicians’ to incorporate frailty assessment
into the overall evaluation of elderly patients. Perhaps
more importantly, the Frail-VIG index can reliably
discriminate between different degrees of frailty (up to
seven categories in the present study) and can accurately
predict 12- and 24-month mortality. The results of the
current study support the use of the Frail-VIG index in
routine clinical practice. Additional research is needed to
confirm its validity in a wider range of populations.
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